ID   8305C
AC   CVCL_1053
SY   8305c; 8305-C; 8305C_1
DR   BTO; BTO:0000919
DR   CLO; CLO_0001510
DR   CLO; CLO_0050949
DR   CLDB; cl132
DR   CLDB; cl133
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 318
DR   BioSample; SAMN01821670
DR   BioSample; SAMN03470959
DR   BioSample; SAMN03473414
DR   BioSample; SAMN10988447
DR   cancercelllines; CVCL_1053
DR   CCRID; 3101HUMSCSP540
DR   Cell_Model_Passport; SIDM00997
DR   CGH-DB; 53-1
DR   ChEMBL-Cells; CHEMBL3308706
DR   ChEMBL-Targets; CHEMBL1075386
DR   CLS; 305101
DR   Cosmic; 906795
DR   Cosmic; 922364
DR   Cosmic; 2009523
DR   Cosmic; 2054104
DR   Cosmic; 2613247
DR   Cosmic; 2786687
DR   Cosmic-CLP; 906795
DR   DepMap; ACH-001306
DR   DSMZ; ACC-133
DR   DSMZCellDive; ACC-133
DR   ECACC; 94090183
DR   EGA; EGAS00001000978
DR   GDSC; 906795
DR   GEO; GSM886846
DR   GEO; GSM887910
DR   GEO; GSM1669573
DR   IARC_TP53; 21156
DR   ICLC; HTL96026
DR   JCRB; JCRB0824
DR   LiGeA; CCLE_684
DR   LINCS_LDP; LCL-1685
DR   NCBI_Iran; C597
DR   PharmacoDB; 8305C_30_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1053
DR   PubChem_Cell_line; CVCL_1053
DR   RCB; RCB1909
DR   TKG; TKG 0446
DR   Wikidata; Q54605326
RX   PubMed=9177455;
RX   PubMed=9290701;
RX   PubMed=14522906;
RX   PubMed=15613457;
RX   PubMed=16924234;
RX   PubMed=20164919;
RX   PubMed=21566963;
RX   PubMed=22460905;
RX   PubMed=23833040;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30737244;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Japanese.
CC   Doubling time: 43 hours (PubMed=21566963); ~54 hours (DSMZ=ACC-133); ~50 hours (Note=Lot 07252003) (JCRB=JCRB0824).
CC   HLA typing: A*11:01,11:01; B*15:01,54:01; C*01:02,04:01; DQB1*04:02,04:02; DRB1*11:14,11:14 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800Ter (c.8398C>T); ClinVar=VCV001171818; Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP=906795; DepMap=ACH-001306).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP=906795; DepMap=ACH-001306).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Phe90Leufs*14 (c.270delT); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244; PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=14522906; PubMed=21566963; PubMed=30737244; Cosmic-CLP=906795; DepMap=ACH-001306).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=1.04%; East Asian, North=74.78%; East Asian, South=24.09%; South Asian=0%; European, North=0%; European, South=0.09% (PubMed=30894373).
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): Cosmic-CLP=906795; DSMZ=ACC-133; ECACC=94090183; JCRB=JCRB0824; PubMed=25877200; PubMed=30737244; RCB=RCB1909; TKG=TKG 0446
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D13S317: 9
ST   D16S539: 10,11
ST   D18S51: 13,24
ST   D19S433: 14
ST   D21S11: 30,32.2
ST   D2S1338: 17,25
ST   D3S1358: 15
ST   D5S818: 10,13
ST   D7S820: 8 (DSMZ=ACC-133)
ST   D7S820: 8,10 (Cosmic-CLP=906795; ECACC=94090183; JCRB=JCRB0824; PubMed=25877200; PubMed=30737244; RCB=RCB1909; TKG=TKG 0446)
ST   D8S1179: 11,14
ST   FGA: 21,22
ST   Penta D: 10
ST   Penta E: 15,17
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 14,16
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 43
//
RX   PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3;
RA   Satake S., Sugawara I., Watanabe M., Takami H.;
RT   "Lack of a point mutation of human DNA topoisomerase II in
RT   multidrug-resistant anaplastic thyroid carcinoma cell lines.";
RL   Cancer Lett. 116:33-39(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
//
RX   PubMed=15613457; DOI=10.1677/erc.1.00818;
RA   Onda M., Emi M., Yoshida A., Miyamoto S., Akaishi J., Asaka S.,
RA   Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.;
RT   "Comprehensive gene expression profiling of anaplastic thyroid cancers
RT   with cDNA microarray of 25 344 genes.";
RL   Endocr. Relat. Cancer 11:843-854(2004).
//
RX   PubMed=16924234; DOI=10.1038/sj.onc.1209899;
RA   Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.;
RT   "A novel amplification target, DUSP26, promotes anaplastic thyroid
RT   cancer cell growth by inhibiting p38 MAPK activity.";
RL   Oncogene 26:1178-1187(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21566963; DOI=10.3892/ijo.4.3.583;
RA   Ito T., Seyama T., Hayashi Y., Hayashi T., Dohi K., Mizuno T.,
RA   Iwamoto K.S., Tsuyama N., Nakamura N., Akiyama M.;
RT   "Establishment of 2 human thyroid-carcinoma cell-lines (8305C, 8505C)
RT   bearing p53 gene-mutations.";
RL   Int. J. Oncol. 4:583-586(1994).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//